Results 101 to 110 of about 8,545 (211)

CCL3 and IL‐7 Synergistically Enhance CAR‐T Efficacy in Solid Tumors

Advanced Science, Volume 13, Issue 49, 3 September 2026.
Synergistic delivery of CCL3 and IL‐7 by CAR‐T cells overcomes the immunosuppressive tumor microenvironment by enhancing cell infiltration, survival, and local immune reprogramming. This also establishes positive feedback that amplifies anti‐tumor activity and memory responses in both CAR‐T and endogenous T cells, presenting a robust therapeutic ...
Huanpeng Chen, Xiaoyun Luo, Huixin Gao, Yujing Ke, Yu Zhan, Xiaoting Xu, Xiaoxiao Xiong, Fengjiao Wei, Si Yang, Zhonghua Liu, Bolan Yu, Zhaofeng Huang, Yingjie Bian   +12 more
wiley   +1 more source

Linked collectors and determiners for: Colección de Macroinvertebrados Acuáticos de la Amazonia Colombiana.

Natural history specimen data linked to collectors and determiners held within, "Colección de Macroinvertebrados Acuáticos de la Amazonia Colombiana".
Bionomia
core   +1 more source

Tumor‐Specific Delivery of CD28 siRNA via Lyso‐PC C‐16 Modified Lipid Nanoparticles Overcomes Anti‐PD‐1 Resistance by Remodeling Tumor Microenvironment

Advanced Science, Volume 13, Issue 49, 3 September 2026.
This study develops 16:0 LPC‐modified lipid nanoparticles (LPC‐LNPs) with cancer cell specificity by exploiting altered tumor lipid metabolism. LPC‐LNPs encapsulating Cd28 small interfering RNA (LPC‐LNP‐Cd28) knock down cancer cell CD28 without affecting T cells, inflame the tumor microenvironment, and overcome anti‐PD‐1 resistance.
Yangyang Chai, Keyu Wang, Jiali Fang, Shaorui Jia, Yansong Shi, Wanfeng Gao, Xinpeng Liu, Jiaqiang Li, Zenghui Cui, Yazhi Qian, Xiaosu Chen, Dan Ding, Xuetao Cao   +12 more
wiley   +1 more source

Targeting DNGR‐1 with Fangchinoline Elevates Dendritic Cell Antigen Cross‐Presentation‐Mediated Antitumor Immunity in Melanoma

Advanced Science, Volume 13, Issue 50, 7 September 2026.
Fangchinoline is identified as a small‐molecule DNGR‐1 modulator that enhances dendritic‐cell cross‐presentation of tumor antigens. By engaging DNGR‐1 and activating Syk–Nox2 signaling, it promotes phagosomal ROS, antigen escape, MHC‐I presentation, and CD8+ T‐cell priming, thereby strengthening antitumor immunity and sensitizing tumors to PD‐1 ...
Yuan Liao, Zhenyang Ren, Jing Zhou, He Luo, Yuling Li, Dan Chen, Yuxiao Jiang, Canzhe Li, Mengyi Zheng, Anqi Li, Yao Wang, Yang Zhang, Dingye Wang, Yanjun Jiang, Jiangyong Gu, Biaoyan Du, Yafei Shi, Fang Liu, Jianyong Xiao, Kun Wang   +19 more
wiley   +1 more source

Regnase-1 in cDC1 controls T cell priming and shapes the dynamics of experimental autoimmune encephalomyelitis

Frontiers in Immunology
IntroductionMultiple sclerosis is a chronic inflammatory demyelinating disease of the central nervous system (CNS), in which various immune cells contribute to disease progression, yet the role of dendritic cells (DCs) remains incompletely understood ...
Xingyu Rong, Hai Wang, Shintaro Muraoka, Takuya Uehata, Masanori Yoshinaga, Tsuneyasu Kaisho, Osamu Takeuchi   +6 more
doaj   +1 more source

cDC1s Promote Atherosclerosis via Local Immunity and Are Targetable for Therapy

Circulation Research
BACKGROUND: Atherosclerosis is characterized by immune cell accumulation in the arterial wall and adaptive CD4 + T helper 1 immunity contributes to atherosclerosis development. However, how conventional dendritic cells (DCs) orchestrate this adaptive response remains controversial ...
Miguel Galán, Laura Fernández-Méndez, Vanessa Núñez, Marcos Femenía-Muiña, Pau Figuera-Belmonte, Elena Moya-Ruiz, Sarai Martínez-Cano, Elena Hernández-García, Manuel Rodrigo-Tapias, Ana Rodríguez-Ronchel, Carlos Relaño-Rupérez, Stefanie K. Wculek, Alberto Benguria, Ana Dopazo, Sandrine Henri, Suin Jo, Tian-Tian Liu, Bernard Malissen, Kenneth M. Murphy, Almudena R. Ramiro, Susana Carregal-Romero, Jesús Ruiz-Cabello, Iñaki Robles-Vera, David Sancho   +23 more
openaire   +4 more sources

Dendritic cell-targeted therapy expands CD8 T cell responses to bona-fide neoantigens in lung tumors

Nature Communications
Cross-presentation by type 1 DCs (cDC1) is critical to induce and sustain antitumoral CD8 T cell responses to model antigens, in various tumor settings.
Lucía López, Luciano Gastón Morosi, Federica La Terza, Pierre Bourdely, Giuseppe Rospo, Roberto Amadio, Giulia Maria Piperno, Valentina Russo, Camilla Volponi, Simone Vodret, Sonal Joshi, Francesca Giannese, Dejan Lazarevic, Giovanni Germano, Patrizia Stoitzner, Alberto Bardelli, Marc Dalod, Luigia Pace, Nicoletta Caronni, Pierre Guermonprez, Federica Benvenuti   +20 more
doaj   +1 more source

Eye‐Brain Neuroimmune Axis Enables Long‐Term Survival in Glioblastoma by Modulating Brain Immune Surveillance and Neuronal Excitability

Advanced Science, Volume 13, Issue 52, 18 September 2026.
The eye–brain neuroimmune axis triggers immune activation and disrupts pathological neuronal connectivity to extend glioblastoma survival. ABSTRACT As an anatomical extension of the central nervous system (CNS), the eye harbors rich neural and immune interfaces with the brain. However, the integrated immunological and neurological nexus between the eye
Mingyue Cui, Lulu Qian, Binbin Chu, Xuan Qin, Menglin Wu, Minke Wu, Tongyu He, Baochuan Zhang, Bin Song, Yao He   +9 more
wiley   +1 more source

The role of cDC1s in vivo: CD8 T cell priming through cross-presentation [version 1; referees: 3 approved]

F1000Research, 2017
The cDC1 subset of classical dendritic cells is specialized for priming CD8 T cell responses through the process of cross-presentation. The molecular mechanisms of cross-presentation remain incompletely understood because of limited biochemical analysis ...
Derek Theisen, Kenneth Murphy
doaj   +1 more source

Oncogenic Mutations and Tumor Microenvironment Alterations in Diffuse Large B‐Cell Lymphoma With Bulky Disease

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Background Bulky disease represents a clinically aggressive subset of diffuse large B‐cell lymphoma (DLBCL) associated with adverse clinical outcomes. The aim of this study was to investigate the influence of oncogenic mutations and tumor microenvironment alterations on bulky disease in DLBCL.
Yu‐Qing Wang, Yue Wang, Zhi‐Shan Du, Xin‐Yun Huang, Yan Dong, Shuang Tian, Di Fu, Shu Cheng, Li Wang, Peng‐Peng Xu, Sheng‐Jin Fan, Shu‐Ye Wang   +11 more
wiley   +1 more source